AGRADECEMOS A IRV ARONS EL TRABAJO QUE HA REALIZADO ACTUALIZANDO ESTA TABLA EN DONDE CON TODO RIGOR, INCLUYE DATOS DE LAS ORGANIZACIONES QUE ESTÁN HACIENDO QUE SEA POSIBLE LA INVESTIGACIÓN DE LAS DISTROFIAS DE RETINA. EN CASI TODOS LOS CASOS ESTÁN EN LA PRIMERA O SEGUNDA FASE. SI NECESITA ALGÚN DATO MÁS, NO DUDE EN […]Leer Más "ENSAYOS CLÍNICOS (DATOS ACTUALIZADOS, ESTADO, PACIENTES, SPONSORS, FASES Y OTRAS INFORMACIONES"
Techniques for regenerating neurons damaged by glaucoma, which have had good results in animals, have improved vision in humans in a small preliminary trial. We’ve made a lot of progress,” said Jeffrey Goldberg, MD, from the University of California at San Diego. No matter what causes the initial injury to retinal ganglion cells, they can’t […]Leer Más "NEUROREGENERATION RESEARCH PROMISING FOR GLAUCOMA"
Regeneron Pharmaceuticals announced that the FDA has approved Eylea (aflibercept) injection for the treatment of diabetic retinopathy in patients with diabetic macular edema (DME), according to a company news release. In 2014, the FDA granted Eylea breakthrough therapy designation and priority review for the treatment of diabetic retinopathy in patients with DME. Diabetic retinopathy coupled […]Leer Más "EYLEA RECEIVES FDA APPROVAL FOR THE TREATMENT OF DIABETIC RETINOPATHY IN PATIENTS WITH DME"
MARLBOROUGH, Mass. 17 March 15– Ocata Therapeutics, Inc. (“Ocata”), a leader in the field of regenerative ophthalmology, today announced that the company has received written formal guidance from the European Medicines Agency (EMA) related to the advancement of its Retinal Pigment Epithelium Program (RPE) into a pivotal clinical trial for Stargardt’s Macular Degeneration (SMD). We […]Leer Más "Pivotal Clinical Trial Program Design for Stargardt’s Macular Degeneration"